NCT03755947View on ClinicalTrials.gov

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

February 1, 2021

Conditions
B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
Interventions
DRUG

Ibrutinib

Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.

DRUG

Obinutuzumab

Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.

DRUG

Venetoclax

Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.

Trial Locations (1)

52763

Grupo Cooperativo de Hemopatías Malignas, Huixquilucan

All Listed Sponsors
lead

Grupo Cooperativo de Hemopatías Malignas

OTHER

NCT03755947 - Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter